Arcutis Biotherapeutics, Inc.·4

Feb 4, 8:35 PM ET

Matsuda Masaru 4

4 · Arcutis Biotherapeutics, Inc. · Filed Feb 4, 2026

Research Summary

AI-generated summary of this filing

Updated

Arcutis (ARQT) General Counsel Masaru Matsuda Sells Shares

What Happened

  • Masaru Matsuda, Arcutis Biotherapeutics SVP General Counsel and Corporate Secretary, sold a total of 40,638 shares on February 2, 2026 in open-market transactions, generating aggregate proceeds of approximately $1,027,293. The reported line-item weighted average prices were $25.50 (7,983 shs), $24.97 (8,562 shs), $25.24 (19,379 shs) and $25.63 (4,714 shs). These were sales (not purchases) and are routine in nature.

Key Details

  • Transaction date: 2026-02-02; Form 4 filed 2026-02-04 (timely within reporting window).
  • Line items:
    • 7,983 shs @ $25.50 = $203,554
    • 8,562 shs @ $24.97 = $213,793
    • 19,379 shs @ $25.24 = $489,126
    • 4,714 shs @ $25.63 = $120,820
  • Aggregate: 40,638 shares, ~$1,027,293 total proceeds.
  • Shares owned after transaction: Not specified in the provided excerpt of the Form 4.
  • Notable footnotes:
    • Sales were to cover tax withholding on vested RSUs granted Jan 12, 2024 (25% vest annually on Feb 1) (tax-withholding sale).
    • Transactions were effected pursuant to a 10b5-1 trading plan adopted June 5, 2025 (plan ends Sept 4, 2026).
    • Reported prices are weighted averages; the filing discloses individual trade price ranges across the sales (roughly $24.50 to $25.74 across all lots) and offers to provide per-trade details on request.

Context

  • These were sales to satisfy tax-withholding obligations on vested restricted stock units, executed under a preplanned 10b5-1 program. Such tax-withholding sales are common and do not necessarily indicate management sentiment about the company.

Insider Transaction Report

Form 4
Period: 2026-02-02
Matsuda Masaru
See Remarks
Transactions
  • Sale

    Common Stock

    [F1][F2]
    2026-02-02$25.50/sh7,983$203,554142,658 total
  • Sale

    Common Stock

    [F3][F4]
    2026-02-02$24.97/sh8,562$213,793134,096 total
  • Sale

    Common Stock

    [F3][F5]
    2026-02-02$25.24/sh19,379$489,126114,717 total
  • Sale

    Common Stock

    [F3][F6]
    2026-02-02$25.63/sh4,714$120,820110,003 total
Footnotes (6)
  • [F1]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligation in connection with the vesting of Restricted Stock Units ("RSUs"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer.
  • [F2]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.745 to $25.68, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  • [F3]The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on June 5, 2025, by the Reporting Person, with a plan end date of September 4, 2026.
  • [F4]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.50 to $25.42, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  • [F5]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.55 to $25.55, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  • [F6]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.56 to $25.74, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Signature
/s/ Latha Vairavan, as Attorney-in-Fact for Masaru Matsuda|2026-02-04

Documents

1 file
  • 4
    wk-form4_1770255345.xmlPrimary

    FORM 4